AN2 THERAPEUTICS INC's ticker is and the CUSIP is 037326105. A total of 37 filers reported holding AN2 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,768 | -52.1% | 3,095 | -74.7% | 0.00% | – |
Q2 2023 | $103,836 | -59.4% | 12,216 | -52.9% | 0.00% | – |
Q1 2023 | $255,791 | +8.6% | 25,916 | +4.9% | 0.00% | – |
Q4 2022 | $235,525 | +2.8% | 24,714 | +87.7% | 0.00% | – |
Q3 2022 | $229,000 | +1661.5% | 13,166 | +703.3% | 0.00% | – |
Q2 2022 | $13,000 | – | 1,639 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Monashee Investment Management LLC | 433,330 | $6,530,000 | 1.89% |
RA Capital Management | 3,666,663 | $55,257,000 | 1.21% |
BVF INC/IL | 1,616,665 | $24,363,000 | 0.98% |
Avidity Partners Management LP | 688,330 | $10,373,000 | 0.22% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 584,136 | $8,803,000 | 0.20% |
COWEN AND COMPANY, LLC | 60,278 | $908,000 | 0.09% |
Woodline Partners LP | 150,000 | $2,261,000 | 0.04% |
Alyeska Investment Group, L.P. | 125,000 | $1,884,000 | 0.02% |
Citadel Advisors | 1,419,851 | $20,593,000 | 0.00% |
Anson Funds Management LP | 2,500 | $38,000 | 0.00% |